Chakravartty, A.
2 papers on CoChat
Most cited papers
- Verified
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 281
- Verified
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 83
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free